Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | CPA1 | P15085 | 2/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.56 |
| ▸ | FPR2 | P25090 | 5/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468791 | 1.00 | MME (0.63) | MMENPSR1NAALAD2L3MBTL1ACE | |
| SCHEMBL5943645 | 1.00 | MME (0.63) | MMENPSR1NAALAD2L3MBTL1ACE | |
| SCHEMBL14263358 | 0.87 | PTPN1 (0.55) | MMENPSR1NAALAD2ACECPA1 | |
| SCHEMBL15743886 | 0.86 | HPGDS (0.53) | MME | |
| SCHEMBL13536303 | 0.86 | ALDH1A1 (0.55) | MMEL3MBTL1 | |
| SCHEMBL1696507 | 0.85 | MME (0.67) | MMENPSR1NAALAD2L3MBTL1ACE | |
| SCHEMBL18180178 | 0.85 | NAALAD2 (0.78) | MMENPSR1NAALAD2L3MBTL1FPR2 | |
| SCHEMBL547223 | 0.85 | MME (0.67) | MMENPSR1NAALAD2L3MBTL1ACE | |
| SCHEMBL19969196 | 0.85 | NAALAD2 (0.78) | MMENPSR1NAALAD2L3MBTL1FPR2 | |
| SCHEMBL547222 | 0.85 | MME (0.67) | MMENPSR1NAALAD2L3MBTL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GILEAD SCIENCES, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SERPINB1, ABCC1, SERPINB6 | MME 30/4885NPSR1 752/4885NAALAD2 381/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | MME 145/4885NPSR1 4160/4885NAALAD2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.